Tuberous sclerosis complex (TSC) is a genetic disorder characterized by the development
of a variety of benign tumors along with an increased risk of malignancy. Mechanism
of disease is related to the mTOR pathway.
1
In spite of this, individual features have different natural histories, and it is
difficult to predict the extent to which a child with newly diagnosed disease is affected.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Pediatric NeurologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Possible mechanisms of disease development in tuberous sclerosis.Lancet. 2008 Jan; 9: 73-79
- Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.Pediatr Drugs. 2012; 14: 51-60
- Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.Lancet. 2013; 9: 817-824
- Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.Cancer Treat Rev. 2013; 39: 784-792
Article info
Publication history
Published online: May 29, 2014
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
